OCA TO MAKE SECOND SUBMISSION TO PBAC REGARDING NIRAPARIB
OCA is making a re submission to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding Niraparib. This will be for the use of niraparib as a first line treatment for platinum-sensitive, high grade serous ovarian, fallopian tube, or primary peritoneal cancer. OCA made a submission on behalf of our community in 2021, when Niraparib for first line treatment was initially considered by PBAC. The submission last year wasn’t successful, however Niraparib will be reconsidered by the committee at their next meeting in March 2022.
We are thankful to those who have contributed to our previous submissions, or made their own direct submissions. If you have not yet had a chance to have your say, we encourage you to become involved by making a direct submission via the consumer comments form on the PBAC website by 5pm on Thursday 27th January, 2022.
Alternatively if you have any comments or observations you would like OCA to include on your behalf, please don’t hesitate to email our specialist nurses via firstname.lastname@example.org
We understand this process can be confusing, so we have put together some Frequently Asked Questions that may be useful.
For any enquiries about the submission, or other information or support, please speak with one of our ovarian cancer nurses via Helpline on 1300 660 334 (during business hours).
FREQUENTLY ASKED QUESTIONS
What is Niraparib and how is it different to Olaparib?
Niraparib is a type of targeted therapy called a PARP inhibitor.
PARP stands for Poly-ADP Ribose Polymerase. It is a protein that helps cells repair themselves if they become damaged. PARP inhibitors stop the PARP from repairing cancer cells. The only PARP inhibitor currently listed on the Pharmaceutical Benefits Scheme (PBS) for use in Australia is Olaparib, which is only available to those with a BRCA mutation.
Niraparib has shown benefit in those with and without a BRCA mutation, so approval of Niraparib would allow a greater number of women with ovarian cancer to access PARP inhibitor medications.
You can access the article in the New England Journal of Medicine entitled ‘Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer’ here.
What is the Pharmaceutical Benefits Scheme (PBS)?
The PBS is the main mechanism through which the Government subsidises the cost of medications used by the community. Medicines can only be included on the PBS if recommended for listing by the Pharmaceutical Benefits Advisory Committee (PBAC).
What is the Pharmaceutical Benefits Advisory Committee (PBAC)?
PBAC is an independent expert body that includes health professionals, consumer nominees and an industry nominee.
How and when will we know if the application is successful?
The outcomes of each PBAC meeting are available on the PBS website 6 weeks after each meeting (this meeting is scheduled for March 2022).
How can I know if I am eligible and access medications like this or other new treatment options?
Whilst OCA endeavours to update our community on new treatments available, we recommend women discuss eligibility for drugs with their specialist doctor/treatment team, who are best able to advise on treatment options specific to your individual situation, including compassionate access schemes and clinical trials.